TC BioPharm advances cancer therapy trials, raises 8M - Investing.com
| TCBPW Stock | USD 0.02 0.0002 1.32% |
Slightly above 58% of all TC BioPharm's sophisticated investors are looking to take a long position. The analysis of the overall investor sentiment regarding TC BioPharm plc suggests that some traders are interested. TC BioPharm's investing sentiment can be driven by a variety of factors including economic data, TC BioPharm's earnings reports, geopolitical events, and overall market trends.
TCBPW |
TC BioPharm advances cancer therapy trials, raises 8M Investing.com
Read at news.google.com
 |
TC BioPharm Fundamental Analysis
We analyze TC BioPharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
TC BioPharm is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
TC BioPharm plc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TC BioPharm stock to make a market-neutral strategy. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics with similar companies.
Peers
TC BioPharm Related Equities
| SANA | Sana Biotechnology | 3.12 | ||||
| FATE | Fate Therapeutics | 1.20 | ||||
| RCUS | Arcus Biosciences | 0.26 | ||||
| XFOR | X4 Pharmaceuticals | 0.16 | ||||
| CRBU | Caribou Biosciences | 0.55 | ||||
| KPTI | Karyopharm Therapeutics | 0.78 | ||||
| HOOK | Hookipa Pharma | 5.61 |
Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.